HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pravachol OTC Marketing Retailer Involvement Anticipated By BMS

This article was originally published in The Tan Sheet

Executive Summary

A Pravachol OTC marketing program designed to emphasize the "importance of keeping the doctor in the loop" would include point-of-purchase messages encouraging physician consultation, Bristol-Myers Squibb Rx-to-OTC Marketing Senior Director Patricia Kriger told FDA advisory committees July 14.

You may also be interested in...

OTC Statin Physician Follow-Up Label Comprehension Not Shown - FDA

Merck and Bristol Myers-Squibb should design label comprehension studies that do not assume consumers would understand how to use Mevacor and Pravachol in an OTC setting, FDA's Karen Lechter, PhD, advised during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13-14.

Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA

Bristol-Myers Squibb may need to better demonstrate consumers' ability to make self-selection choices based on appropriate cholesterol levels in order to convince FDA that an OTC version of Pravachol is approvable.

Toll-Free Screening, Advice Service Would Enchance OTC Mevacor - Merck

Merck would support an OTC version of its statin drug Mevacor with an ambitious customer education program that would ensure proper usage of the cholesterol-lowering medication, the firm stated July 13 at a joint meeting of FDA's Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts